medigraphic.com

2007, Number S4

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S4)

Some physiopathologic features of metabolic syndrome

Posadas RC

Language: Spanish
References: 36
Page: 42-47
PDF size: 118.55 Kb.


ABSTRACT

Metabolic syndrome (MS) is a common condition strongly associated with the development of type 2 diabetes and coronary heart disease (CHD). High triglycerides (TG) and low high density lipoprotein cholesterol (HDL-C) often occur together and represent the fundamental dyslipidemia of patients with MS. This abnormal lipoprotein profile is a major risk factor for premature cardiovascular disease. This review briefly discusses new findings on structure and functions of HDL in the atherogenic dyslipidemic condition known as MS. While the knowledge of the association between HDL-C and CHD began with the observation of an inverse relationship between HDL-C values and CHD risk, information in recent years shows the important role of HDL function in the pathogenesis of atherosclerosis. HDL particles are heterogeneous in structure, intravascular metabolism and antiatherogenic activity. Reductions in HDL-C concentrations, as seen in MS, are frequently associated with an abnormal HDL subclass distribution, altered HDL chemical composition, reduced anti-inflamatory and antioxidative properties, and low capacity to promote cholesterol efflux. Deficiency of HDL particle number and attenuated antiaterogenic activity favor accelerated atherosclerosis. These data justify renewed emphasis on low HDL-C as a major risk factor in the prevention and treatment of CHD. Pharmacological interventions that increase HDL-C can also improve the quality and biological activities of HDL particles. Fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, and reconstituted HDL are being investigated. Patients with MS constitute a high risk group that would particularly benefit from intervention to rise HDL-C.


REFERENCES

  1. Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002; 106: 3143.

  2. Kahn R, Buse J, Ferrannini E, Stern M: The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28: 2289-2304.

  3. Grundy MS, Cleeman IJ, Daniels RS, Donato AK, Eckel HR, Franklin AB, et al: Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752.

  4. Aguilar SCA, Rojas R, Gómez PFJ, Valles V, Ríos TJM, Franco A, et al: High prevalence of metabolic syndrome in Mexico. Arch Med Res. 2004; 35: 76-81.

  5. Posadas RC, Zamora GJ, Posadas SR, Cardoso SG: Prevalencia de síndrome metabólico y de sus componentes en pacientes con cardiopatía isquémica. XX congreso interamericano de Cardiología. Archivos de Cardiología de México. 2006; 75: S4-135. Resumen No. 539.

  6. Caracas PN, Zamora GJ, Posadas SR, Cardoso SG, Yamamoto KL, Posadas RC: Association between Homeostasis Model Assessment of Insulin Resistance and the Metabolic Syndrome in Mexican adolescents. (87th Annual Meeting of the Endocrine Society, San Diego 2005; p 348 [Abstract P1-713].): 1-2, 2006.

  7. Aguilar SCA, Olaiz G, Valles V, Ríos TJM, Gómez PFJ, Rull AJ, et al: High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001; 42: 1298-1307.

  8. Posadas SR, Zamora GJ, Yamamoto KL, Cardoso SG, Posadas RC: Prevalence of Dyslipidemia in Mexican Urban Adolescents. XIV International Symposium on Atherosclerosis. Atherosclerosis. 2006; Supl. 7: 82. Resumen No. 163.

  9. Libby P: Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol. 2001; 88:3N-8N.

  10. Blanche PJ, Gong EL, Forte TM, Nichols AV: Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981; 665: 408-419.

  11. Asztalos FB, Sloop HC, Wong L, Roheim SP: Comparison of apo A-I-containing subpopulations of dog plasma and prenodal peripheral lymph: evidence for alteration in subpopulations in the interstitial space. Biochim Biophys Acta. 1993; 1169: 301-304.

  12. Silverman DI, Ginsburg GS, Pasternak RC: High-density lipoprotein subfractions. Am J Med. 1993; 94: 636-645.

  13. von Eckardstein, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994; 5: 404-416.

  14. Cheung MC, Brown BG, Wolf AC, Albers JJ: Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 1991; 32: 383-394.

  15. Shah KP; Kaul S, Nilsson J, Cercek B: Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I. Circulation. 2001; 104: 2376-2383.

  16. Campos H, Roederer OG, Lussier-Cacan S, Davignon J, Krauss MR: Predominance of Large LDL and Reduced HDL2 Cholesterol in Normolipidemic Men With Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 1995; 15: 1043-1048.

  17. Calabresi L, Gomaraschi M, Franceschini G: Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside. Arterioscler Thromb Vasc Biol. 2003; 23: 1724-1731.

  18. Howard BV, Mayer-Davis JE, Goff D, Zaccaro JD, Laws A, Robbins CD, Saad FM, Selby J, Hamman FR, Krauss MR, Haffner SM: Relationships between insulin resistance and lipoproteins in nondiabetic African-Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Metabolism. 1998; 47: 1174-1179.

  19. Bhalodkar NC, Blum S, Rana T, Kitchappa R, Bhalodkar AN, Enas EA: Comparison of high-density and low-density lipoprotein cholesterol subclasses and sizes in Asian Indian women with Caucasian women from the Framingham Offspring Study. Clin Cardiol. 2005; 28: 247-251.

  20. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, et al: Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance. Diabetes. 2003; 52: 453-462.

  21. Festa A, Williams K, Hanley JGA, Otvos DJ, Goff CD, Wagenknetch EL, et al: Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance. Atherosclerosis Study. Circulation. 2005; 111: 3465-3472.

  22. Pérez MO, Torres TM, Posadas RC, Vidaure GV: Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chem Acta. 2006; in press.

  23. Asztalos FB, Cupples LA, Demissie S, Horvath VK, Cox EC, Batista CM, et al: High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004; 24: 2181-2187.

  24. Asztalos FB, Collins LD, Cupples A, Demissie S, Horvath VK, Bloomfield EH, et al: Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005; 25: 2185-2191.

  25. Sheikh-Ali AA, Kuvin JT, Karas RH: High-density lipoprotein cholesterol in the cardiovascular equation: does the “good” still count? Atherosclerosis. 2005; 180: 217-223.

  26. Kontush A, Chantepie S, Chapman MJ: Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress. Arterioscler Thromb Vasc Biol. 2003; 23: 1881-1888.

  27. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al: Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity. J Clin Endocrinol Metab. 2004; 89: 4963-4971.

  28. Kontush A, de Faria EC, Chantepie S, Chapman MJ: A normotriglyceridemic, low HDL-cholesterol phenotype is characterized by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 2005; 182: 277-285.

  29. Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170: 191-203.

  30. Cockerill WG, Rye KA, Gamble JR, Vadas AM, Barter JP: High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules. Arterioscler Thromb Vasc Biol. 1995; 15: 1987-1994.

  31. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G: Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol. Arterioscler Thromb Vasc Biol. 2002; 22: 656-661.

  32. Medina UXA, Pérez MOA, Huesca GC, Zamora GJ, Posadas RC: Functional and metabolic characteristics of HDL in healthy subjects and cardiovascular disease (CVD) patients. XIV International Symposium on Atherosclerosis. Atherosclerosis. 2006; Supl. 7: 534. Resumen No. 186.

  33. Brites FD, Bonavita CD, De Geitere C, Cloes M, Delfly B, Yael MJ, et al: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis. 2000; 152: 181-192.

  34. Dullaart RP van Tol A: Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab Invest. 2001; 61: 69-74.

  35. Alenezi MY, Marcil M, Blank D, Sherman M, Jacques G Jr: Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? J Clin Endocrinol Metab. 2004; 89: 761-764.

  36. Sandholfer A, Kaser S, Ritsch A, Laumer M, Engl J, Paulweber B, et al: Cholesterol ester transfer protein in metabolic syndrome. Obesity. 2006; 14: 812-818.




2020     |     www.medigraphic.com